Kieren A. Marr

Kieren A. Marr

Auto-generated profile, based on publicly available information

Kieren A. Marr

Fred Hutchinson Cancer Research Center, Seattle

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2002 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
KMKieren A. Marr
Kieren A. Marr
RCRachel A. Carter
Rachel A. Carter
FCFulvio Crippa
Fulvio Crippa
AWAnna Wald
Anna Wald
LCLawrence Corey
Lawrence Corey
Reports have focused on the emergence of moulds as pathogens in recipients of hematopoietic stem cell transplants. To review the incidence of and risks for mould infections, we examined the records of 5589 patients who underwent hematopoietic stem cell transplantation at the Fred Hutchinson Cancer Research Center (Seattle) from 1985 through 1999. After 1992, the incidence of invasive aspergillosis increased in allograft recipients and remained high through the 1990s. Infections with non-fumigatus Aspergillus species, Fusarium species, and Zygomycetes increased during the late 1990s, especially in patients who received multiple transplants. Although infection caused by Scedosporium species was common in patients who had neutropenia, infection caused by Zygomycetes typically occurred later after transplantation, when patients had graft-versus-host disease. The overall 1-year survival rate was equally poor (∼20%) for all patients with mould infections. The results of the present study demonstrate the changing epidemiology of mould infections, emphasizing the increasing importance of amphotericin B–resistant organisms and the differences in risks and outcome of infection with different filamentous fungi.

15 December 2002 in Blood
Verified
Journal Article
Closed access
KMKieren A. Marr
Kieren A. Marr
RCRachel A. Carter
Rachel A. Carter
MBMichael Boeckh
Michael Boeckh
PMPaul Martin
Paul Martin
LCLawrence Corey
Lawrence Corey
The incidence of postengraftment invasive aspergillosis (IA) in hematopoietic stem cell transplant (HSCT) recipients increased during the 1990s. We determined risks for IA and outcomes among 1682 patients who received HSCTs between January 1993 and December 1998. Risk factors included host variables (age, underlying disease), transplant variables (stem cell source), and late complications (acute and chronic graft-versus-host disease [GVHD], receipt of corticosteroids, secondary neutropenia, cytomegalovirus [CMV] disease, and respiratory virus infection). We identified risk factors associated with IA early after transplantation (≤ 40 days) and after engraftment (41-180 days). Older patient age was associated with an increased risk during both periods. Chronic myelogenous leukemia (CML) in chronic phase was associated with low risk for early IA compared with other hematologic malignancies, aplastic anemia, and myelodysplastic syndrome. Multiple myeloma was associated with an increased risk for postengraftment IA. Use of human leukocyte antigen (HLA)–matched related (MR) peripheral blood stem cells conferred protection against early IA compared with use of MR bone marrow, but use of cord blood increased the risk of IA early after transplantation. Factors that increased risks for IA after engraftment included receipt of T cell–depleted or CD34-selected stem cell products, receipt of corticosteroids, neutropenia, lymphopenia, GVHD, CMV disease, and respiratory virus infections. Very late IA (> 6 months after transplantation) was associated with chronic GVHD and CMV disease. These results emphasize the postengraftment timing of IA; risk factor analyses verify previously recognized risk factors (GVHD, receipt of corticosteroids, and neutropenia) and uncover the roles of lymphopenia and viral infections in increasing the incidence of postengraftment IA in the 1990s.

15 September 2004 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
KMKieren A. Marr
Kieren A. Marr
MBMichael Boeckh
Michael Boeckh
RCRachel A. Carter
Rachel A. Carter
HKHyung Woo Kim
Hyung Woo Kim
LCLawrence Corey
Lawrence Corey
Background. Aspergillosis therapy with amphotericin, azoles, or echinocandins is associated with substantial mortality, ranging from 30% to 80%, depe

15 June 2005 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
KMKieren A. Marr
Kieren A. Marr
MLMichel Laverdiere
Michel Laverdiere
AGAnja Gugel
Anja Gugel
WLWendy Leisenring
Wendy Leisenring
Background. Reported sensitivity of the galactomannan enzyme immunoassay as an early diagnostic test for invasive aspergillosis (IA) has been widely

1 August 2004 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KMKieren A. Marr
Kieren A. Marr
SBS. Arunmozhi Balajee
S. Arunmozhi Balajee
LMLisa McLaughlin
Lisa McLaughlin
MTMarc Tabouret
Marc Tabouret
CBChristopher Bentsen
Christopher Bentsen
TWThomas J. Walsh
Thomas J. Walsh
Invasive aspergillosis (IA) is a frequent complication of blood or marrow transplantation. Previous studies have reported that the Aspergillus galact

1 January 2000 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KMKieren A. Marr
Kieren A. Marr
KSKristy Seidel
Kristy Seidel
Theodore C. WhiteTheodore C. White
Theodore C. White
RBRaleigh A. Bowden
Raleigh A. Bowden
The prophylactic use of fluconazole is common in blood and marrow transplant (BMT) recipients. To evaluate how fluconazole has influenced the develop